Đánh giá hiệu quả tiêm nội nhãn Bevacizumab điều trị bệnh võng mạc đái tháo đường tăng sinh tại Bệnh viện 19-8

This study aims to assess the efficacy of intravitreal Bevacizumab in enhancing visual acuity among individuals diagnosed with proliferative diabetic retinopathy. Methods: A prospective study was conducted involving 40 patients diagnosed with proliferative diabetic retinopathy who received treatment at the Ophthalmology Department of 19-8 Hospital from January 2023 to November 2023. The patients underwent monthly intravitreal injections and were evaluated over a period of 5 months. Results: Forty eyes (from 40 patients) diagnosed with proliferative diabetic retinopathy received a series of five intravitreal Bevacizumab injections. A majority of patients exhibited improved visual acuity after 5 months of treatment, with the most significant enhancement observed following the second injection, during which 10 (25%) patients experienced significant enhancement. The highest visual acuity was attained in the fifth month (0.78 logMAR units). The temporal trend of visual improvement demonstrated statistical significance (p = 0.004). An overall assessment after 5 months of treatment revealed that 15 eyes (37.5%) experienced a significant improvement in visual acuity, 17 eyes (42.5%) maintained stable visual acuity, and 8 eyes (20%) exhibited decreased or unchanged visual acuity. Conclusion: The administration of intravitreal Bevacizumab in patients with proliferative diabetic retinopathy demonstrated a relatively high success rate, with 80% of the study participants experiencing substantial and stable improvement in visual acuity after 5 months of treatment.